Phase I study of the oral GLP ‐1 receptor agonist DA ‐ 302168S : Safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults

Sep 25, 2025Diabetes, obesity & metabolism

Safety and body effects of the oral drug DA-302168S in healthy and overweight adults

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Mean weight loss in overweight/obese subjects was between -5.67% and -7.26%, significantly greater than the placebo effect of -2.90%.

DA-302168S was generally well tolerated, with nausea being the most frequently reported side effect.
Pharmacokinetic profiles were dose proportional, showing moderate variability among individuals.
Significant metabolic improvements were observed, including reduced glucose fluctuations and lowered HbA1c levels.
Optimised lipid profiles were also noted alongside the weight loss in the study participants.

AI simplified

AIM: This first-in-human Phase I study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DA-302168S, a novel oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1RA).

MATERIALS AND METHODS: The study comprised three parts: a single ascending dose (SAD) phase in healthy adults (Phase Ia; 2.5-50 mg), and two multiple ascending dose (MAD) phases-a 28-day study in healthy adults (Phase Ib) and a 28-day, weekly-titration study in overweight/obese adults (Phase Ic; 7.5-30 mg QD). All parts were randomised, double-blind, and placebo-controlled. Safety and tolerability were the primary endpoints.

RESULTS: DA-302168S was generally well tolerated, with gastrointestinal events (primarily nausea) being the most common adverse events. PK profiles were dose proportional with moderate inter-individual variability across SAD and MAD phases. Robust, dose-dependent efficacy was observed in overweight/obese subjects (Phase Ic), with mean weight loss ranging from -5.67% to -7.26%, significantly exceeding placebo (-2.90%). This was accompanied by significant metabolic improvements, including reduced glucose fluctuations, lowered HbA1c, and optimised lipid profiles.

CONCLUSIONS: DA-302168S demonstrates a favourable safety and PK profile, coupled with substantial, dose-dependent weight loss and metabolic benefits. These results strongly support its continued development as a promising once-daily oral therapy for obesity and type 2 diabetes.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (XML) ↗View full text ↗

Phase I study of the oral GLP ‐1 receptor agonist DA ‐ 302168S : Safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief